NCT03188666 - A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

September 16, 2019

Study Completion Date

September 16, 2021

Conditions

Fibrodysplasia Ossificans Progressiva

Interventions

DRUG

REGN2477

Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.

DRUG

Matching placebo

Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.

Trial Locations (11)

Giannina Gaslini Institute, Genova

University of Pennsylvania, Philadelphia

Hospital Universitario Ramon y Cajal, Madrid

Vanderbilt University, Nashville

Mayo Clinic, Rochester

Hopital Cochin, Paris

Hopital Lariboisiere,Hospitalier Universitaire Nord, Paris

Toronto General Hospital, Toronto

VU University Medical Center, Amsterdam

Szpital Wojewodzki Nr 2, Rzeszów

Royal National Orthopaedic Hospital, Brockley Hill, Stanmore

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY